• In combination with standard immunosuppressive therapy for the first-line treatment of severe aplastic anemia. (drugs.com)
  • The FDA has granted Breakthrough Therapy designation to Promacta for use in combination with standard immunosuppressive therapy for severe aplastic anaemia. (europeanpharmaceuticalreview.com)
  • PROMACTA is a prescription medicine used to treat people with severe aplastic anemia (SAA) in combination with standard immunosuppressive therapy as the first treatment for adults and children 2 years of age and older. (promacta.com)
  • It is not known if PROMACTA is safe and effective in children with chronic HCV or previously treated SAA, in children younger than 1 year with ITP, or children younger than 2 years when used in combination with standard immunosuppressive therapy as the first treatment for SAA. (promacta.com)
  • The Food and Drug Administration (FDA) expanded the approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy to include first-line use in newly diagnosed adult and pediatric patients aged 2 years and older with severe aplastic anemia. (oncnursingnews.com)
  • Indeed, most patients can respond to therapy that suppresses the immune system, usually ATG and cyclosporine. (rarediseases.org)
  • Are you or your child taking cyclosporine for aplastic anemia? (nih.gov)
  • This study is testing whether the medicine sirolimus helps prevent the return of aplastic anemia after stopping cyclosporine. (nih.gov)
  • Only two-thirds of patients with acquired aplastic anaemia respond to standard immunosuppressive treatment with horse antithymocyte globulin plus cyclosporine. (bjh.be)
  • This clinical trial will randomize 234 children/AYA over 3.3-4.7 years at a 1:1 ratio between initial treatment with immune suppression therapy (IST) with horse ATG (hATG)/cyclosporine (CsA) versus well- matched (9-10/10 allele) unrelated donor (URD) bone marrow transplantation (BMT) using a regimen of rabbit ATG (rATG)/fludarabine/cyclophosphamide and 200 cGy TBI. (ucsf.edu)
  • INTRODUCTION - Biologic therapies typically do not cause the global immunosuppression that is characteristic of traditional immunosuppressive drugs, such as glucocorticoids, cyclosporine , methotrexate , and azathioprine . (medilib.ir)
  • Although the research study centers had a high coverage of health services, the underreporting of cases of aplastic anemia in selected regions can be discussed. (haematologica.org)
  • 1 A recent review of the epidemiology of aplastic anemia shows that most cases of aplastic anemia appear to be secondary to the immunological destruction of the hematopoietic cells. (haematologica.org)
  • Most cases of aplastic anemia are idiopathic, meaning the underlying cause is unknown. (dana-farber.org)
  • Promacta (eltrombopag olamine) is a thrombopoietin receptor agonist that is used to increase low blood platelet counts (thrombocytopenia) in certain people with chronic immune thrombocytopenia (ITP) and severe aplastic anemia. (drugs.com)
  • To treat thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. (drugs.com)
  • Symptoms are dependent on the severity of the anemia, leukopenia, and thrombocytopenia. (rarediseases.org)
  • This Phase 2, non-randomized pilot study of eltrombopag in aplastic anemia patients with immunosuppressive therapy refractory thrombocytopenia will test the safety and potential efficacy of eltrombopag treatment patients with refractory thrombocytopenia following immunosuppression for aplastic anemia. (drugpatentwatch.com)
  • The primary objective is to assess the safety and efficacy of the oral thrombopoietin receptor agonist (TPO-R agonist) eltrombopag in aplastic anemia patients with immunosuppressive-therapy refractory thrombocytopenia. (drugpatentwatch.com)
  • Consider discontinuing therapy if severe and unremitting thrombocytopenia or neutropenia occurs. (pfizermedicalinformation.com)
  • Criteria for diagnosis of MDS consist of anemia, thrombocytopenia, or neutropenia that persist for six months or longer, dysplasia greater than 10% in at least one bone marrow cell lineage, and MDS associated clonal cytogenetic abnormalities or molecular markers. (standardofcare.com)
  • In patients with unexplained anemia, thrombocytopenia, or neutropenia without dysplasia in the bone marrow but with abnormal chromosome activity in 5, 7 or 13 the diagnosis is consistent with MDS and occurs in less than 10% of patients with MDS. (standardofcare.com)
  • MDS with lower risk transformation to AML are typically characterized by low myeloblast percentages, fewer genetic variants, or by genetic variants associated with a better prognosis, less severe anemia, thrombocytopenia, or neutropenia. (standardofcare.com)
  • MDS with higher risk of transformation to AML are typically characterized by a higher percentage of myeloblasts, more genetic variants or genetic variants associated with the worse prognosis with a greater degree of anemia, neutropenia, or thrombocytopenia. (standardofcare.com)
  • It's also rare to have isolated thrombocytopenia without anemia in MDS, so other causes (such as immune thrombocytopenia or a drug effect) should be ruled out if a patient presents with isolated thrombocytopenia and no anemia or neutropenia. (dermatologyadvisor.com)
  • Inpatient care for patients with aplastic anemia may be needed during periods of infection and for specific therapies, such as antithymocyte globulin (ATG) or HCT. (medscape.com)
  • The British Committee for Standards in Haematology also recommends irradiated blood products for all patients receiving antithymocyte globulin (ATG) therapy. (medscape.com)
  • He underwent allogeneic bone marrow transplantation after completing two courses of immunosuppressive therapy with antithymocyte globulin and cyclosporin A. (biomedcentral.com)
  • OVERVIEW - Biologic therapies that can increase the risk of infectious diseases include antithymocyte globulin, monoclonal antibodies to T and B cells, anticytokine therapies, agents that disrupt T cell costimulation signals, and agents that interfere with T cell inhibitory (checkpoint) signals. (medilib.ir)
  • The cases were patients with diagnosis of aplastic anemia confirmed through biopsy or bone marrow aspiration, selected through an active search of clinical laboratories, hematology clinics and medical records. (haematologica.org)
  • Nonetheless, the availability of such "genetic testing" has revealed increasing numbers of individuals who by clinical criteria appear to have idiopathic aplastic anemia (AA) and appear phenotypically normal yet have molecular hallmarks of congenital marrow failure syndromes. (ashpublications.org)
  • The specific medications administered depend on the choice of therapy and whether it is supportive care only, immunosuppressive therapy, or hematopoietic cell transplantation. (medscape.com)
  • Severe aplastic anemia (SAA) is a life-threatening blood disease which can be effectively treated with immunosuppressive drug regimens or allogeneic stem cell transplantation. (drugpatentwatch.com)
  • Initially described in pediatric patients with leukemic diseases, it has been gradually reported in adults with hematological malignancies and non-hematological conditions, such as leukemia, lymphoma, multiple myeloma, aplastic anemia, and also myelodysplastic syndromes, as well as being associated with other immunosuppressive causes such as AIDS treatment, therapy for solid tumors, and organ transplantation. (encyclopedia.pub)
  • Aplastic anemia (moderate to severe) in patients unsuitable for bone marrow transplantation. (pfizermedicalinformation.com)
  • The usefulness of ATGAM has not been demonstrated in patients with aplastic anemia who are suitable candidates for bone marrow transplantation or in patients with aplastic anemia secondary to neoplastic disease, storage disease, myelofibrosis, Fanconi's syndrome, or in patients known to have been exposed to myelotoxic agents or radiation. (pfizermedicalinformation.com)
  • Survival in severe aplastic anemia (SAA) has markedly improved in the past 2 decades because of advances in hematopoietic stem cell transplantation, immunosuppressive and biologic drugs, and supportive care. (pedemmorsels.com)
  • The nature of the underlying disease process - For example, a patient who is given an immunosuppressive drug shortly after undergoing hematopoietic cell transplantation for malignancy may be at greater risk than a patient receiving the same drug for chronic, stable rheumatologic disease. (medilib.ir)
  • An experienced multidisciplinary team in close consultation with the primary transplantation centre should perform the rehabilitation therapy. (mdpi.com)
  • Causes of mortality in those patients were severe viral pneumonia, post-transplantation hemophagocytic syndrome and meningeal GVHD refractory to ruxolitinib. (scielo.org)
  • In acquired aplastic anemia, an almost complete absence of hematopoietic stem cells results in low levels of red and white blood cells and platelets (pancytopenia). (rarediseases.org)
  • The clinical presentation of patients with aplastic anemia includes signs and symptoms related to the decrease in bone marrow production of hematopoietic cells. (medscape.com)
  • Aplastic anemia is a disorder of the hematopoietic stem cell that results in a loss of blood cell precursors, hypoplasia or aplasia of bone marrow, and cytopenias in two or more cell lines (red blood cells, white blood cells, and/or platelets). (merckmanuals.com)
  • The term aplastic anemia commonly implies a panhypoplasia of the bone marrow with cytopenias in at least two hematopoietic lineages. (merckmanuals.com)
  • Aplastic Anemia" = tri-lineage peripheral blood cytopenia due to reduced or absent production of hematopoietic cells without cellular infiltration . (pedemmorsels.com)
  • Some individuals with acquired aplastic anemia also have another disorder at the same time, called paroxysmal nocturnal hemoglobinuria (PNH). (rarediseases.org)
  • Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disorder characterized by complement-mediated intravascular hemolysis, bone marrow failure, and severe thrombophilia ( 1 ). (frontiersin.org)
  • The thrombopoietin-receptor agonist eltrombopag is approved for use in patients with severe aplastic anemia who fail to respond adequately to immunosuppressive therapy. (medscape.com)
  • However, 44% (11 of 25) of patients had at least some hematologic response to therapy at 12 weeks, with 9 of the 11 patients no longer needing platelet transfusions at that time. (drugs.com)
  • Severe or very severe aplastic anemia is a hematologic emergency, and care should be instituted promptly. (medscape.com)
  • the incidence rate of 21 studies was 5.3% in patients hospitalized for hematologic malignancies, high-dose chemotherapy for solid tumors, or aplastic anemia, while another cohort study found it in 3.5% of 317 severely neutropenic patients [ 4 ] [ 5 ] . (encyclopedia.pub)
  • Aplastic anemia (AA) is a hematologic condition characterized by bone marrow hypoplasia or aplasia resulting in pancytopenia. (haematologica.org)
  • Eltrombopag and improved hematopoiesis in refractory aplastic anemia [published correction appears in N Engl J Med. (drugs.com)
  • Methods: A retrospective analysis was performed on patients with severe GVHD refractory to corticosteroids. (scielo.org)
  • This procedure is typically used to treat blood cancers such as leukemia, lymphoma, and multiple myeloma, as well as other disorders such as sickle cell anemia and thalassemia. (vanyahealth.com)
  • Acquired aplastic anemia is a rare, serious blood disorder, due to failure of the bone marrow failure to produce blood cells. (rarediseases.org)
  • Although bone marrow failure can occur secondary to other disorders, most aplastic anemia is due to the immune system mistakenly targeting the bone marrow (autoimmunity). (rarediseases.org)
  • The symptoms of acquired aplastic anemia occur as a consequence of the bone marrow failing to produce enough blood cells. (rarediseases.org)
  • It is believed that PNH arises in the setting of autoimmune acquired aplastic anemia and bone marrow failure. (rarediseases.org)
  • Paul Ehrlich introduced the concept of aplastic anemia in 1888 when he reported the case of a pregnant woman who died of bone marrow failure. (medscape.com)
  • Different factors contribute to residual anemia during eculizumab treatment: underlying bone marrow dysfunction, residual intravascular hemolysis and the emergence of C3-mediated extravascular hemolysis. (frontiersin.org)
  • The trial aims to improve the response of AML patients to the second stage of AML treatment, termed consolidation therapy, by eliminating the minimal residual disease left in the bone marrow after the first stage of the standard treatment regimen, called induction therapy. (technologynetworks.com)
  • 4 Although bone marrow transplants have increased the survival rate of patients with AA, most people do not have access to this therapy, and fatality rates of the disease remain high. (haematologica.org)
  • Hepatitis-associated aplastic anemia is a common syndrome in patients with bone marrow failure. (biomedcentral.com)
  • Furthermore, due to its inhibition of cellular growth, interference with oncogene expression and augmentation of lymphocyte cytotoxicity for target cells, IFN-α may cause bone marrow suppression, including potentially severe cytopenias and, very rarely, AA [ 11 ]. (biomedcentral.com)
  • Aplastic anemia is a rare but serious blood disorder that occurs when the body's bone marrow cannot produce enough healthy blood cells to function properly. (dana-farber.org)
  • Researchers believe most cases of idiopathic aplastic anemias result from the immune system mistakenly attacking the bone marrow , interrupting healthy blood cell production. (dana-farber.org)
  • Immunosuppressive therapy , which uses medicines to suppress the immune system's attack of bone marrow to allow the bone marrow to start producing blood cells normally again. (dana-farber.org)
  • The goal of the conditioning therapy is to remove the diseased bone marrow cells to prepare for the new healthy ones. (dana-farber.org)
  • Conditions associated with bone marrow failure such as aplastic anemia with hypocellular marrow, typical bone marrow findings of MDS are a hypercellular marrow for a persons age, dysplasia in 1 to 3 lineages manifested by pseudo Pelger-Huet nuclei, hypogranular neutrophils, micro megakaryocytes, and/or ringed sideroblasts, glass Siri glass, and increased myeloblasts in a subset of patients. (standardofcare.com)
  • SAA can be cured with immune suppressive therapy or a bone marrow transplant. (ucsf.edu)
  • Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. (ucsf.edu)
  • The diagnosis of Fanconi anemia must be excluded by diepoxybutane (DEB) or equivalent testing on peripheral blood or marrow. (ucsf.edu)
  • The bone marrow in MDS is usually hypercellular for age, but about 10% of cases are accompanied by a hypocellular marrow, and such cases may be difficult to distinguish from aplastic anemia. (dermatologyadvisor.com)
  • Traditional Chinese herbal medicine in the supportive management of patients withchronic cytopaenic marrow diseases e A phase I/II clinical study, Complementary Therapies in Clinical Practice (2011), doi:10.1016/j.ctcp.2011.01.004 Y.-c. (healthdrugpdf.com)
  • However, at least 50% of the etiology of aplastic anemia remains unexplained. (haematologica.org)
  • It is a severe disease and its etiology has been attributed to medications, 1 , 2 chemicals, 1 - 3 and environmental factors. (haematologica.org)
  • Non-myeloablative, so-called mini transplant (microtransplantation) procedures, have been developed requiring smaller doses of preparative chemotherapy and radiation therapy, allowing HSCT to be conducted in the elderly and other patients who would otherwise be considered too weak to withstand a conventional treatment regimen. (wikipedia.org)
  • Chemotherapy is still the current standard treatment for hematological malignancy and febrile neutropenia is a common complication of chemotherapy in most patients [ 1 ]. (biomedcentral.com)
  • Before receiving the transplant, patients undergo immunosuppressive conditioning therapy, which includes chemotherapy and/or radiation. (dana-farber.org)
  • In this type of transplant, the patient's own stem cells are collected before the high-dose chemotherapy and/or radiation therapy is given. (vanyahealth.com)
  • After the chemotherapy and radiation therapy, the stored stem cells are thawed and returned to the patient's body. (vanyahealth.com)
  • This type of transplant is used when the patient's own cells are not damaged or diseased, but are being used as a rescue therapy after high-dose chemotherapy or radiation therapy. (vanyahealth.com)
  • Development of Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma. (u-tokyo-hemat.com)
  • Individuals affected with acquired aplastic anemia are also at risk that it will evolve into another similar disorder known as myelodysplasia. (rarediseases.org)
  • However, it was not until 1904 that Anatole Chauffard named this disorder aplastic anemia. (medscape.com)
  • Pure Red Blood Cell Aplasia Acquired pure red blood cell aplasia is a disorder of erythroid precursors that results in an isolated normocytic anemia. (merckmanuals.com)
  • Children may inherit a disorder that predisposes them to develop aplastic anemia. (dana-farber.org)
  • It can be necessary to treat underlying illnesses for the rare cases in which aplastic anemia is caused from a previous illness or disorder. (dana-farber.org)
  • Therapies used in more than one primary immunodeficiency disorder include the following: IV immune globulin (IVIG) is effective replacement therapy in most forms of antibody deficiency. (ferienwohnung-uelsen.de)
  • How quickly does Promacta work in ITP and severe aplastic anemia? (drugs.com)
  • A total of 95% of the patients were able to receive antiviral therapy after treatment with Promacta. (drugs.com)
  • It is unclear exactly how quickly Promacta + combination immunosuppressive therapy works in previously untreated patients with severe aplastic anemia. (drugs.com)
  • However, 87% (95% CI 75-100) of patients treated with Promacta once daily for the first 6 months of their treatment plan (cohort 3 Study US01T) had either a complete or partial response to Promacta + combination immunosuppressive therapy at 3 months. (drugs.com)
  • It is unclear exactly how quickly Promacta works in patients with severe aplastic anemia who have not responded to previous immunosuppressive therapy. (drugs.com)
  • PROMACTA may increase your risk of liver problems that may be severe and possibly life-threatening. (promacta.com)
  • Candidates for HSCTs include pediatric cases where the patient has an inborn defect such as severe combined immunodeficiency or congenital neutropenia with defective stem cells, and also children or adults with aplastic anemia who have lost their stem cells after birth. (wikipedia.org)
  • Most infections fail to respond to antifungal therapy unless there is resolution of the patient's neutropenia. (ventsistema.net)
  • The toxicity of anticancer treatment will continue to be a significant problem until highly selective therapies for malignant cells are developed [ 6 ] . (encyclopedia.pub)
  • Combination regimens are often the standard treatment. (encyclopedia.pub)
  • Targeting a second AML treatment line, BL-8040 is scheduled to commence a Phase 2b trial, as a consolidation treatment for AML patients who have responded to standard induction treatment, in the first quarter of 2015. (technologynetworks.com)
  • Contraception: Advise females of reproductive potential to use effective contraception during treatment with ATGAM and for up to 10 weeks after cessation of therapy. (pfizermedicalinformation.com)
  • In addition, to the best of our knowledge there are no reported cases of patients with chronic hepatitis C virus infection developing aplastic anemia associated with pegylated interferon alpha 2a treatment. (biomedcentral.com)
  • We report the case of a 46-year-old Greek man who developed severe aplastic anemia during treatment with pegylated interferon alpha 2a for chronic hepatitis C virus infection. (biomedcentral.com)
  • The combination of a specific environmental precipitant represented by the hepatitis C virus infection, an altered metabolic detoxification pathway due to treatment with pegylated interferon alpha 2a and a facilitating genetic background such as polymorphism in metabolic detoxification pathways and specific human leukocyte antigen genes possibly conspired synergistically in the development of aplastic anemia in this patient. (biomedcentral.com)
  • Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. (medicines.org.uk)
  • Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. (medicines.org.uk)
  • Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. (dovepress.com)
  • Treatment for aplastic anemia varies depending on classification and other factors. (dana-farber.org)
  • Patients enrolled in the trial had no prior systemic anti-cancer treatment for melanoma, except surgery for the melanoma lesion(s) and/or adjuvant radiation therapy after neurosurgical resection for central nervous system lesions. (bms.com)
  • The diagnosis, evaluation, and treatment of aplastic anemia varies between institutions. (pedemmorsels.com)
  • This trial will compare time from randomization to failure of treatment or death from any cause of IST versus URD BMT when used as initial therapy to treat SAA. (ucsf.edu)
  • The medicines and procedures in this study are standard for treatment of SAA. (ucsf.edu)
  • The huge clinical experience and high competence of the doctors working in the department allow them to achieve excellent treatment results even in the most severe cases. (bookinghealth.com)
  • The patient is offered a comprehensive treatment, including intensive care to eliminate side effects associated with the tumor and therapy, development of individual recommendations on nutrition, physiotherapeutic measures and psycho-oncological care. (bookinghealth.com)
  • This small study offers positiveresults and provides the basis for future larger studies which should randomize patients with MDS, MFand AA managed with standard Western medical treatment to without and with upfront combinationswith TCM herbs. (healthdrugpdf.com)
  • The rationale for the proposed research is that when we are able to identify patients who are at particularly high risk for unresponsiveness to standard treatment and subsequent mortality, we can porpose customized treatment plans. (cryostem.org)
  • Added to this, there are patients who do not improve on any immunosuppressive treatment, with subsequent deteriorated quality of life and high mortality. (scielo.org)
  • This study is testing whether adding the medicine eltrombopag to standard treatments is a better way to treat severe aplastic anemia. (nih.gov)
  • My principle research interests are in the prevention and therapy of graft-versus-host disease (GVHD) and in the use of graft-versus-leukemia to eradicate blood disorders. (harvard.edu)
  • The presentation of hyper IgE syndrome is highly variable, which makes it easy to confuse the diagnosis with that of severe atopy or other rare immunodeficiency disorders. (ferienwohnung-uelsen.de)
  • This has included immnosuppressive therapy, Western Medicine (WM) in the healthcare system in China and is haemopoietic stem cell transplant and targeted therapies that are often integrated with WM to a variable degree in the management still in various stages of clinical trial. (healthdrugpdf.com)
  • Dyskeratosis congenita and Schwachmai-Diamond Syndrome also cause aplastic anemia. (pedemmorsels.com)
  • The epidemic caused by the infection of severe acute respiratory syndrome coronavirus 2 omicron variant broke out in Shanghai in Mar. 2022. (bvsalud.org)
  • Details of the criteria for their physicians' knowledgThis often raises concerns on the syndrome classification, composition of each standard formulation part of the treating WM physician when attempting to consider and herbs allowed for addition are shown in possible adverse reactions which may include a deterioration of The TCM herbs were imported in bulk from a regular source in cytopaenia, organ toxicity or drugeherb interaction. (healthdrugpdf.com)
  • Patients with aplastic anemia require transfusion support until the diagnosis is established and specific therapy can be instituted. (medscape.com)
  • The originally produced document was published in 2017 and was informed by the published guidelines on the use of irradiated blood components by the British Committee for Standards in Haematology, 2010, and the guidelines for prevention of transfusion-associated graft-versus-host disease (TA-GVHD) by the Australian and New Zealand Society of Blood Transfusion, 2011. (nacblood.ca)
  • Symptoms of aplastic anemia are those of anemia, bleeding, and infection. (rarediseases.org)
  • What are some of the common symptoms of severe aplastic anemia? (promacta.com)
  • Aplastic anemia symptoms occur because of the bone marrow's failure to produce enough blood cells to support the body's needs. (dana-farber.org)
  • Acquired aplastic anemia can be classified as moderate, severe or very severe, depending on stability of blood cell count and other symptoms. (dana-farber.org)
  • Complementary Therapies in Clinical Practice xxx (2011) 1e5 WM and is widely consumed by patients on their own often without changes in the patients' symptoms. (healthdrugpdf.com)
  • Other causes of aplastic anemia can include radiation, medications, infections (including hepatitis or HIV), or certain toxins. (dana-farber.org)
  • It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. (lookformedical.com)
  • The donor's cells are not as well matched to the patient's cells as in a standard allogeneic transplant, which increases the risk of complications such as graft-versus-host disease (GVHD) and graft rejection. (vanyahealth.com)
  • However, 20-40% of patients without transplant options do not respond to immunosuppressive therapies, and have persistent severe cytopenias, requiring regular platelet transfusions, which are expensive and inconvenient, and are a risk for further serious bleeding complications. (drugpatentwatch.com)
  • Complete normalization of hemoglobin (complete and major hematological response), is seen in no more than one third of patients, while the remaining continue to experience some degree of anemia (good and partial hematological responses), in some cases requiring regular red blood cell transfusions (minor hematological response). (frontiersin.org)
  • The presence of severe/life-threatening conditions and chronic graft-vs-host disease increased the odds of health care utilization across all domains. (bvsalud.org)
  • The controls did not have either aplastic anemia or chronic diseases. (haematologica.org)
  • These results suggested that ATG/PTCy (low-dose) can reduce both acute and chronic GVHD as compared with standard ATG-based prophylaxis using maternal donor or collateral relatives at particular high GVHD risk. (biomedcentral.com)
  • The concomitant use of other immunosuppressive medications with synergistic adverse immunologic effects - In addition, the use of multiple biologic agents is rarely studied formally but is becoming increasingly common in clinical practice. (medilib.ir)
  • Although the anemia is often normocytic, mild macrocytosis can also be observed in association with stress erythropoiesis and elevated fetal hemoglobin levels. (medscape.com)
  • Development of TP53 mutations over the course of therapy for acute myeloid leukemia. (cdc.gov)
  • The onset of aplastic anemia usually is insidious, often occurring over weeks or months after exposure to a virus, medication or toxin (eg, insecticides, benzene), though occasionally it can be acute. (merckmanuals.com)
  • Using proteomics, it has been shown that plasma concentration of Suppression of Tumorigenicity 2 (ST2), accurately stratified patients according to risk of non-response to acute GvHD therapy in large retrospective sets. (cryostem.org)
  • This study is testing whether low doses of the medicine danazol help prevent telomeres from getting shorter and reduce signs of damage from aplastic anemia or related conditions. (nih.gov)
  • Participants in this study must be 3 years or older and have a telomere disease and signs of aplastic anemia, lung disease such as pulmonary fibrosis, or liver disease. (nih.gov)
  • All other treatments for MDS are only palliative in nature, although some therapies can extend survival and improve quality of life. (dermatologyadvisor.com)